No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
PGNY240517C35000
- 0.05
- 0.000.00%
15min DelayClose May 13 15:59 ET
0.05High0.02Low
0.02Open0.05Pre Close6 Volume4.01K Open Interest35.00Strike Price17.00Turnover128.14%IV27.92%PremiumMay 17, 2024Expiry Date0.00Intrinsic Value100Multiplier3DDays to Expiry0.05Time Value100Contract SizeAmericanOptions Type0.0365Delta0.0222Gamma548.00Leverage Ratio-0.0310Theta0.0001Rho20.01Eff Leverage0.0022Vega
Intraday
- 5D
- 1D
News
Progyny Price Target Cut to $30.00/Share From $48.00 by Barclays
Progyny Price Target Cut to $30.00/Share From $48.00 by Barclays
Progyny Is Maintained at Overweight by Barclays
Progyny Is Maintained at Overweight by Barclays
Barclays Maintains Overweight on Progyny, Lowers Price Target to $30
Barclays analyst Sarah James maintains Progyny (NASDAQ:PGNY) with a Overweight and lowers the price target from $48 to $30.
Progyny (NASDAQ:PGNY) Has More To Do To Multiply In Value Going Forward
Analysts Conflicted on These Healthcare Names: Insulet (PODD) and Progyny (PGNY)
Fertility Solutions-Focused Progyny Stock Sinks After Soft Guidance; Analyst Says 'Can No Longer Underwrite Sustained Healthy Growth In Forecasts'
On Thursday, Progyny Inc (NASDAQ:PGNY) reported first-quarter sales of $278.1 million, up 7.6% year over year, missing the consensus of $289.46 million, primarily due to the increased number of client